|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Date  | June 2018 | 17.06.2019 | 25.07.2019 | 19.09.2019 | October 2019 | 01.11.2019 | 04.05.2020 | 25.09.2020 | 16.10.2020 | 09.04.2021 | 30.04.2021 | 23.07.2021 | 23.08.2021 | 23.11.2021 | 21.12.2021 |
| Clinical manifestations | first pemphigus symptoms  | surgery  | lung involvement  | lack of pulmonary improvement  | consultation with pulmonologist | clinical improvement  |  |  |  | increased frequency of dyspnoea  |
| intravenous immunoglobulins | immunosuppressive dose 2g/kg every four weeks | supplementary dose0.4g/kg according to IgG levels | increase in dose1g/kg every three weeks |  | supplementary dose0.4g/kg according to IgG levels |  |
| Prednisone (per os) |   |   | Increase (1mg/kg/d)  | Decrease (0,5mg/ kg/d) |  |  |  |  |  |  |  |  |  |
| Rituximab (intravenous infusion) |  |  |  375mg/m2 every 2 weeks |  |  |  |  |  |  |  |  |  |  |  |  |
| tocilizumab (intravenous infusion) |  |  |  | every 2 weeks | every 3 weeks | every 4 weeks | every 3 weeks |
|  |  |  |  |   |   |  8 mg/kg | 10mg/kg | 12mg/kg |   |   |   | 12mg/kg  | 12mg/kg |
| fluticasone & salmeterol (per inhalation) |  |  |  |  |   |  4 at  |  50µg |   |   |   |   |   |   |   |   |
| interleukin-6 (pg/mL) |  | 3.4 |  | 6.2 |  | 53.8 |  |  |  |  | 75.3 | 21 |  |  | 30 |

TABLE 1 The dates and doses of immunosuppressive and immunomodulatory medications in presented patient.